Pushkal Garg, EVP Chief R&D at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 4,713 shares at $319.03 ($1.5M) on 2026-03-04, disclosed to the SEC on 2026-03-06.
Seasonal sale ($1.5M) by EVP Chief R&D — this insider has traded ALNY in March in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $319.03 | 106 | $34K | 2.2% |
| 2 | $320.01 | 102 | $33K | 2.1% |
| 3 | $320.81 | 215 | $69K | 4.5% |
| 4 | $321.82 | 289 | $93K | 6.1% |
| 5 | $323.01 | 350 | $113K | 7.4% |
| 6 | $323.84 | 767 |
| $248K |
| 16.3% |
| 7 | $324.88 | 272 | $88K | 5.8% |
| 8 | $325.67 | 208 | $68K | 4.4% |
| 9 | $322.33 | 654 | $211K | 13.8% |
| 10 | $323.55 | 740 | $239K | 15.7% |
| 11 | $324.59 | 510 | $166K | 10.9% |
| 12 | $326.08 | 500 | $163K | 10.7% |
| Total | $323.53 avg | 4,713 | $1.5M | 100% |
| Filing → |
| ALNY | SELL | 2026-02-17 | $695K | — | Filing → |
| ALNY | SELL | 2026-01-14 | $548K | — | Filing → |
| ALNY | SELL | 2025-10-03 | $5.3M | — | Filing → |